Cargando…

Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience

PURPOSE: Chemotherapy and multi-targeted tyrosine kinase inhibitors (TKI) are important treatments for advanced soft tissue sarcomas, but the following treatment remains unclear after the failure of these drugs. This retrospective study investigated the efficacy and safety of multi-targeted TKI rech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jie, Deng, Yao-Tiao, Wu, Xin, Jiang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987272/ https://www.ncbi.nlm.nih.gov/pubmed/33776477 http://dx.doi.org/10.2147/CMAR.S300430

Ejemplares similares

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
por: O'Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma
por: Canter, Robert J, et al.
Publicado: (2014)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
por: Zhang, Ren‐Shu, et al.
Publicado: (2022)

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature
por: Deguchi, Shoichi, et al.
Publicado: (2017)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study
por: Liu, Zengjun, et al.
Publicado: (2023)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
por: Lin, Xinqing, et al.
Publicado: (2022)

Management of Advanced Adult Soft Tissue Sarcoma
por: Bramwell, Vivien H. C.
Publicado: (2003)

Systemic Therapy for Advanced Soft Tissue Sarcomas
por: Riedel, Richard F
Publicado: (2012)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
por: Albarrán, Víctor, et al.
Publicado: (2022)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
por: Koehler, Viktoria Florentine, et al.
Publicado: (2022)

Immune checkpoint inhibitor resistance in soft tissue sarcoma
por: Eulo, Vanessa, et al.
Publicado: (2022)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
por: Hindi, Nadia, et al.
Publicado: (2020)

Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
por: Strassmann, Dennis, et al.
Publicado: (2021)

Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
por: Marrari, Andrea, et al.
Publicado: (2020)

Soft-tissue Sarcomas
por: Vodanovich, Domagoj Ante, et al.
Publicado: (2018)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
por: Schmitt, Thomas, et al.
Publicado: (2010)

The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy
por: Zhang, Zhusheng, et al.
Publicado: (2022)

Superficial Soft-Tissue Sarcomas Rarely Require Advanced Soft-Tissue Reconstruction following Resection
por: Eward, William C., et al.
Publicado: (2017)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Advances in soft-tissue sarcoma – There are no mistakes, only lessons to learn!
por: Rastogi, Sameer, et al.
Publicado: (2019)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021)

Treatment and prognosis of iliac fossa soft tissue sarcoma: A single‐center study
por: Sun, Wei, et al.
Publicado: (2020)

Retroperitoneal soft tissue sarcoma
por: Zepeda, Ernesto, et al.
Publicado: (2007)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g2rn2r5cuo9bg455gubha66h6f